New-Onset Seizures in Children with HIV

David Bearden MD MSCE Presenting for the CHASE Study team University of Rochester School of Medicine

Acknowledgements and Disclosures

- Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number R01NS094037. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- Research discussed in this talk was supported by grants from the Center for AIDS Research (CFAR), an NIH-funded program (P30 AI 045008).
- Dr. Bearden has served as a consultant for Biogen and Q-State Biosciences.

Outline

• Overview of neurologic complications of HIV

 Brief review of published literature on seizures and HIV

 Results from the Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE) Study Why talk about seizures and HIV? Seizures are common in children with HIV in resource-limited settings

Seizures in children with HIV are potentially preventable and treatable



36.7 MILLION

people worldwide are currently living with HIV/AIDS.

2.1 MILLION CHILDREN

worldwide are living with HIV. Most of these children were infected by their HIV-positive mothers during pregnancy, childbirth or breastfeeding.

How does HIV affect the brain?

- Direct effects
 - HIV-associated Neurocognitive Disorders
 - HIV-associated cerebrovascular disease
 - Primarily mediated through immune activation and inflammation

How does HIV affect the brain?

- Direct effects
 - HIV-associated Neurocognitive Disorders
 - HIV-associated cerebrovascular disease
 - Primarily mediated through immune activation and inflammation

- Indirect Effects
 - Opportunistic Infections
 - CNS Malignancies
 - Primarily mediated through immune suppression

HIV neuropathogenesis



Background

 New-onset seizures relatively common among children with HIV in resourcelimited settings

• 5-17% of adults with HIV developed epilepsy in pre-cART era

Minimal published data in children

Birbeck et al 2012; Kellinghaus et al 2008

Prior Studies in Adults	Most common etiologies for seizures	Other causes	Prevalence	% on ART
Bartolomei (France, 85-90)	Toxoplasmosis	PML HAND Drugs	Not reported	0
Wong (NYU, 1984-88)	Toxoplasmosis	Lymphoma Electrolytes Cryptococcus	11%	0
Pascual-Sedano (Spain, 1999)	Toxoplasmosis Drug toxicity or withdrawal	HAND PML	3%	Not reported
Kellinghaus (Germany, 1992- 2004)	Toxoplasmosis PML	TBM Cryptococcus Drug withdrawal	6.1%	90%
Chanda (India, 2000)	Toxoplasmosis	Crypto; TB; PML; HAND	5%	Not reported
Millogo (Burkina Faso 2000-2004)	Toxoplasmosis	TBM Crypto	Not reported	Not reported

Prior Studies in Children	Most common etiologies for seizures	Other causes	Prevalence	% on ART
Tellechea- Rotta 2003 (Brazil 2003)	CNS Infections	HIVE	6%	Unknown
Samia 2012 (South Africa)	Unknown	TBM Cryptococcus	7.6%	100%
Bearden 2015 (Botswana 2003-2012)	CNS Infections	HIVE	6%	100%
Burman 2019 (South Africa)	Unknown	TBM Other meningitis	23% *	98%

Background: The Epilepsy in Children with HIV in Botswana Study

Methods	Retrospective cohort with nested case control component
Sample	All patients with HIV <18 years old and on ART followed at Princess Marina Hospital Pediatric Center of Excellence in Gaborone, Botswana
Sampling procedure	Electronic and manual search of medical records with prospective verification
Imaging	MRI and/or CT performed in 70% of subjects
Laboratory Testing	Standard Clinical testing. Lumbar puncture was performed in 51% of subjects; available tests included cryptococcal antigen, TB culture, VZV and HSV PCR.



Epilepsy Etiology

Stroke, 3% CM, 3%

HIV Encephalo pathy, 24%

Unknown, 37%

CNS Infection,

32%

Unknown

CNS Infection

HIV EncephalopathyStroke

 Congenital Malformation

Risk Factors for Epilepsy: Univariate analysis

	Odds ratio (with 95% CI)	P-value
CD4 count<200	2.6	0.05
WHO Stage 4	2.8	0.02
Developmental Delay	16.5	<0.001
History of HIVE	20.5	0.004

Risk factors for epilepsy: Multivariable model

 In the multivariable model, only HIVE and history of CD4 count<200 remained significant.

 Since these tend to be late complications of HIV infection, this would suggest that early treatment with ARVs might be helpful in preventing neurologic complications of HIV.



J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 Jun

PMCID: PMC4446226 NIHMSID: NIHMS659034 PMID: 25647527

Published in final edited form as:

J Acquir Immune Defic Syndr. 2015 Jun 1; 69(2): 193–199.

doi: 10.1097/QAI.000000000000563

Early Antiretroviral Therapy is Protective against Epilepsy in Children with Human Immunodeficiency Virus Infection in Botswana

David Bearden, MD,^{1,2,3} Andrew P. Steenhoff, MD,^{2,4} Dennis J. Dlugos, MD, MSCE,¹ Dennis Kolson, MD, PhD,⁵ Parth Mehta, MD,⁶ Sudha Kessler, MD, MSCE,^{1,3} Elizabeth Lowenthal, MD, MSCE,^{2,3,7} Baphaleng Monokwane, MD,⁸ Gabriel Anabwani, MBChB, MMed,⁹ and Gregory P. Bisson, MD, MSCE^{2,3,10}

Author information > Copyright and License information <u>Disclaimer</u>

1.

Limitations of Prior Studies • Old, largely pre-cART era studies Primarily retrospective Determination of etiology not standardized Minimal testing/imaging Mortality not able to be assessed

CHASE

 The Cohort of HIV-associated Seizures (CHASE) is a prospective cohort study examining etiology and outcomes in children with HIV presenting with new onset seizures

HIV AND AIDS IN ZAMBIA

Zambia (2016) 1.2 million people living with HIV 12.4% adult HIV prevalence 59,000 new HIV infections 21,000 AIDS-related deaths 67% adults on antiretroviral treatment **52%** children on antiretroviral treatment

Source: UNAIDS Data 2017

Methods

- Study Design: Prospective Cohort with case control component
- Population: All children with HIV presenting with new onset seizures.
- HIV+ Controls with no history of seizures recruited from outpatient clinics
- Additional study sites at two rural sites (Monze and Chikankata) are enrolling both children and adults



Methods	Longitudinal prospective study
Sample	All patients with HIV presenting to the University Teaching Hospital or one of two rural sites with new-onset seizures.
Sampling procedure	All new admissions to surveyed by study nurse, subjects prospectively enrolled
Instruments	Standardized questionnaire to assess demographics, clinical history, HIV history, nutritional status, and socioeconomic status
Neuropsychological testing	Universal Test of Intelligence-2 Malawi Developmental Inventory
Imaging	MRI and/or CT performed in all surviving subjects at UTH
Laboratory Testing	Serum and CSF Viral load Serum and CSF cryptococcal antigen CSF Gene Xpert, EBV, CMV, JC Virus, HSV, HHV6

Results: Subjects Enrolled





Results: Demographics and Clinical Characteristics

	Urban Site (n=49)	Rural Sites (n=24)
Sex	57% male	58% male
Age in years	6 (IQR 2-11 years range 3 months-16 years)	6 (IQR 2-9 years; range 3 months-14 years)
On ART	54%	33%
Viral load undetectable	1 (3%)	3 (13%)
WHO Stage 4	75%	45%
CD4 < 200	45%	26%

Etiology of Seizures	N (%) Total n=73
CNS Infection (TBM, Cryptococcal meningitis, PML, bacterial meningitis, viral meningoencephalitis)	26 (35%)
HIVE/severe malnutrition	13 (18%)
Hyponatremia	9 (12%)
Nephropathy with hypertensive encephalopathy	3 (4%)
Severe Malaria	2 (3%)
Neurocysticercosis	2 (3%)
Unknown* (Information limited by lack of LP)	18 (25%)

Key Risk Factors for Death: Univariate analysis

Variable	Odds Ratio	P-Value
Hyponatremia (Serum sodium on admission <130)	14.0	0.02
CD4<200	8.9	<0.001
CNS Infection	4.2	0.006
WHO Stage 4	4.0	0.02
Glasgow Coma Scale < 10	3.3	0.02

Risk Factors for Death: Multivariable Analysis

- Low CD4 count
- WHO Stage 4
- Hyponatremia
- Low Lansky score (rating of pre-hospitalization function)
- Age under 5
- Site
- This model explains 58% of the variance in mortality

Key Risk Factors for Recurrence: Univariate analysis

Variable	Odds Ratio	P-Value
Hyponatremia (Serum sodium on admission <130)	Perfect prediction (no recurrence in hyponatremic group)	n/a
Focality	5.0	0.02
Status epilepticus	3.4	0.07
WHO4	2.3	0.2

Key Risk Factors for Seizures: Univariate analysis

Variable	Odds Ratio	P-Value
Undetectable Viral load	0.02	<0.001
CD4<200	6.3	<0.001
WHO Stage 4	2.2	0.005

Risk Factors for Seizures

 In the multivariable analysis, only undetectable viral load and low CD4 count remained significant.

• This model explained 48% of the variance in seizure outcomes

 What drives differences in ART coverage/effectiveness between groups?

Evaluating neighborhood effects

 Location of all urban subjects residences in each group was mapped using Quantitative Geographic Information Systems (QGIS)

 Clustering of cases and socioeconomic characteristics was evaluated using SATscan.





Constituency

* = Neighborhoods with NCC

Access to Running Water

Flush Toilets

Green – HANDZ Case Yellow – CHASE participant Red – Deceased CHASE participant

Conclusions

- Children with HIV and new onset seizures have a high risk of early mortality and seizure recurrence is common.
- Children with HIV presenting with seizures are primarily those who "fall through the cracks" of the HIV treatment cascade
- Early initiation of ART and successful retention in care are likely to reduce incidence of seizures

• Special Thanks to:

• Dr. Gretchen Birbeck, Manoj Matthews, Edward Phiri, Izukanji Sikazwe, Rasford Banda, Gretchen Birbeck, Ifunanya Dallah, Ruth Chama, Namwiya Bowa, Michael Potchen, Ivy Makulu, Lisa Kalungwana Mambwe, Mutinta Muchimba, Roseanna Battista, Omar Siddiqi, Allison Navis, Musa Mwenechanya, Michael Potchen, all participating patients, and the rest of the HANDZ and CHASE teams!

